64. Thrombotic thrombocytopenic purpura
74 clinical trials,   76 drugs   (DrugBank: 19 drugs),   15 drug target genes,   57 drug target pathways

Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04588194
(ClinicalTrials.gov)
November 1, 202030/1/2020Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaRomiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaImmune Thrombocytopenia;Thrombotic Thrombocytopenic PurpuraDrug: Romiplostim;Drug: Rituximab;Drug: DexamethasoneDavid Gomez AlmaguerNULLRecruiting16 Years90 YearsAll12Phase 2Mexico
2NCT04074187
(ClinicalTrials.gov)
October 21, 201914/8/2019A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic PurpuraDrug: Caplacizumab (ALX-0081);Drug: Plasma exchange (PE);Drug: Corticosteroid treatment (Methylprednisolone or prednisolone);Drug: Immunosuppressive treatment (eg, rituximab)SanofiNULLRecruiting18 YearsN/AAll18Phase 2;Phase 3Japan
3EUCTR2017-001117-86-GB
(EUCTR)
25/07/201718/05/2018Elective rituximab in TTPA phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP - Elective rituximab in TTP Acquired thrombotic thrombocytopenic purpura;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Trade Name: Mabthera
Product Name: Mabthera
University College LondonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
52Phase 4United Kingdom
4JPRN-JMA-IIA00160
20/01/201416/01/2014Investigator Initiated Clinical Trial of Rituximab for Thrombotic Thrombocytopenic PurpuraInvestigator Initiated Clinical Trial of Rituximab for Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic PurpuraIntervention type:DRUG. Intervention1:Rituximab, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP, intended dose regimen:1st cycle
Initiate infusion at a rate of 50 mg/hr. In the absence of adverse events such as allergic reaction or infusion reaction, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent cycles
If patients did not experience or experience grade 2 or less severe adverse events such as allergic reaction or infusion reaction during previous cycles, initiate infusion at a rate of 100 mg/hr and increase infusion rate by 100 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
If patients experience grade 3 or more severe adverse events such as allergic reaction or infusion reaction during previous cycles, initiate infusion at a rate of 50 mg/hr and increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr..
Saitama Medical University , Department of General Internal Medicine, Yoshitaka MiyakawaNULLCompleted>=20 YEARS<=79 YEARSBOTH8Phase 2Japan
5NCT01554514
(ClinicalTrials.gov)
August 20128/3/2012Low Dose Rituximab in Thrombotic Thrombocytopenic PurpuraAdjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 DeficiencyThrombotic Thrombocytopenic PurpuraBiological: rituximabWashington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/AAll19Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00907751
(ClinicalTrials.gov)
May 201022/5/2009Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic PurpuraAssociation of Rituximab to Plasma Exchange in Adult Acquired Idiopathic Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic PurpuraDrug: rituximabAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth12Phase 2France
7EUCTR2010-018794-38-IT
(EUCTR)
23/02/201026/07/2010EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPEVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTP THROMBOTIC THROMBOCYTOPENIC PURPURA
MedDRA version: 9.1;Level: LLT;Classification code 10037562
Trade Name: MABTHERA
INN or Proposed INN: Rituximab
FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
8NCT00799773
(ClinicalTrials.gov)
April 200926/11/2008Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)STAR - Study of TTP and Rituximab, A Randomized Clinical TrialThrombotic Thrombocytopenic PurpuraDrug: Rituximab;Procedure: Plasma exchange;Drug: CorticosteroidsNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI);Genentech, Inc.Terminated12 YearsN/AAll3Phase 3United States
9NCT00531089
(ClinicalTrials.gov)
December 200717/9/2007Rituximab in Patients With Relapsed or Refractory TTP-HUSA Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS)Thrombotic Thrombocytopenic Purpura;Hemolytic Uremic SyndromeDrug: RituximabHamilton Health Sciences CorporationCanadian Apheresis Group;Hoffmann-La Roche;McMaster UniversityRecruiting18 YearsN/ABoth60Phase 2Canada
10NCT00937131
(ClinicalTrials.gov)
March 20069/7/2009The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP)Thrombotic Thrombocytopenic Purpura (TTP)Drug: RituximabUniversity College, LondonNULLActive, not recruiting18 Years65 YearsBoth40Phase 2United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2005-002274-30-GB
(EUCTR)
14/12/200504/11/2005A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. - The use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura.A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. - The use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura. Thrombotic Thrombocytopenia PurpuraUniversity College LondonNULLNot Recruiting Female: yes
Male: yes
40Phase 2United Kingdom
12NCT00251277
(ClinicalTrials.gov)
November 20057/11/2005Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraUse of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic PurpuraDrug: RituximabWeill Medical College of Cornell UniversityGenentech, Inc.Withdrawn17 YearsN/ABoth0Phase 1;Phase 2United States